Immunotherapy

Immunotherapy Plus Checkpoint Inhibition in Recruiting Colorectal Cancer Trial

A Phase III multicenter trial evaluating the combination of nivolumab and ipilimumab in patients with mismatch repair-deficient metastatic colorectal cancer is currently recruiting. Preliminary…

Immunotherapy Advances in Colorectal Cancer Treatment

A landmark study demonstrates that pembrolizumab combined with standard chemotherapy significantly extends progression-free survival in patients with mismatch repair-deficient colorectal cancer.